Поиск по каталогу |
(строгое соответствие)
|
- Профессиональная
- Научно-популярная
- Художественная
- Публицистика
- Детская
- Искусство
- Хобби, семья, дом
- Спорт
- Путеводители
- Блокноты, тетради, открытки
A Promenade into monoclonal antibody production processes. In advanced bioprocess industry
В наличии
Местонахождение: Астана | Состояние экземпляра: новый |
Бумажная
версия
версия
Автор: Ujan Banerjee and Rajgourab Ghosh
ISBN: 9786207447763
Год издания: 1905
Формат книги: 60×90/16 (145×215 мм)
Количество страниц: 52
Издательство: LAP LAMBERT Academic Publishing
Цена: 24860 тг
Положить в корзину
Способы доставки в город Алматы * комплектация (срок до отгрузки) не более 2 рабочих дней |
Самовывоз из города Алматы (пункты самовывоза партнёра CDEK) |
Курьерская доставка CDEK из города Москва |
Доставка Почтой России из города Москва |
Аннотация: This book delves into the evolving landscape of monoclonal antibody (mAb) bioprocessing, highlighting advancements crucial for therapeutic applications. It covers the latest technologies in upstream and downstream processing, emphasizing bioreactor systems, cell culture techniques, and purification strategies. Process intensification for increased productivity and cost reduction is a focal point. The study thoroughly addresses critical quality attributes (CQAs) of mAbs, emphasizing the role of process control in maintaining consistent product quality. Safety and efficacy are discussed through analytical methods and quality control procedures. The impact of automation, digitalization, and single-use technologies on scalability and adaptability is analyzed, offering a modern perspective on manufacturing systems. Navigating regulatory considerations and compliance requirements, the book is a comprehensive resource for biopharmaceutical professionals in mAb development. Synthesizing research and industry practices, it highlights the transformative potential of advanced bioprocessing technologies to meet the global demand for high-quality mAb therapeutics.
Ключевые слова: monoclonal antibodies, Bioproduction, Upstream processing, downstream processing, Bioreactor systems, PROCESS INTENSIFICATION, Critical quality attributes (CQAs), Automation, Regulatory considerations, High-quality mAb therapeutics